Skip to Content


by Shefali Luthra and Phil Galewitz, quoting Rachel Sachs (Academic Fellow Alumna)
Kaiser Health News
February 25, 2019

Read the Full Article

From the article:

"And how much would these programs help anyway? While statehouses may be abuzz, in Washington, national politics impedes feasibility. And skeptics question how much relief these initiatives could actually provide.

“I don’t think large-scale importation — given both the size of the United States and the potential for retaliation [by the industry] — is likely to save as much as might be projected,” said Rachel Sachs, an associate law professor at Washington University in St. Louis, who tracks drug-pricing laws."

Read more here!

Read the Full Article

Tags

health law policy   pharmaceuticals   rachel sachs   regulation